Снижение массы тела на 19,3 % к 48-й неделе -- данные исследования фазы III препарата Olatorepatide, двойного селективного агониста ГПП-1/ГИП компании Hansoh, представлены на EASD

Hansoh Pharma is featured in a PRNewswire item tied to the European Association for the Study of Diabetes (EASD) annual conference in Milan, held September 28 to October 2, 2026. The available text states that the company developed a dual selective glucagon-like peptide receptor agonist, but provides no clinical efficacy, safety, regulatory, or financial data to assess a material investment impact.